Literature DB >> 23137031

Fluoxetine induces hepatic lipid accumulation via both promotion of the SREBP1c-related lipogenesis and reduction of lipolysis in primary mouse hepatocytes.

Xue-Min Feng1, Jing Xiong, Hao Qin, Wei Liu, Rui-Ni Chen, Wei Shang, Rui Ning, Gang Hu, Jian Yang.   

Abstract

AIMS: In this study, we investigated the peripheral mechanisms underlying the metabolic side effects of fluoxetine (FLX) by focusing on hepatic lipid metabolism.
METHODS: Primary mouse hepatocytes were prepared from male mice by the two-step perfusion method. The lipid accumulation in primary mouse hepatocytes was analyzed via neutral oil staining. And the lipid metabolism enzymes were determined with RT-PCR and Western blot.
RESULTS: Fluoxetine significantly induced the lipid accumulation in primary mouse hepatocytes. Moreover, FLX increased the acetyl-CoA carboxylase 1 (ACC1) and fatty acid synthase (FAS) expression, which are important enzymes in lipogenesis. Oppositely, Fluoxetine significantly decreased the carboxylesterase 3 (CES3) and carboxylesterase 1 (CES1) expression, which are related to lipolysis. Further study demonstrated FLX-activated SREBP1c, which is one of the most important transcription factors conducting coordinated transcriptional regulation of lipogenesis gene such as ACC1 and FAS. And the increase of lipogenesis gene (ACC1) was abolished by SB203580 but not by pyrrolidine dithiocarbamate (PDTC), suggesting through p38-MAPK pathway.
CONCLUSION: Fluoxetine induces hepatic lipid accumulation via both promotion of the SREBP1c-related lipogenesis and reduction of lipolysis in primary mouse hepatocytes.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137031      PMCID: PMC6493645          DOI: 10.1111/cns.12014

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  7 in total

1.  Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression.

Authors:  Shu-Juan Pan; Yun-Long Tan; Shang-Wu Yao; Yu Xin; Xuan Yang; Jing Liu; Jing Xiong
Journal:  Acta Pharmacol Sin       Date:  2018-05-10       Impact factor: 6.150

2.  Suppression of carboxylesterases by imatinib mediated by the down-regulation of pregnane X receptor.

Authors:  Wenjing Luo; Yu Xin; Xia Zhao; Feng Zhang; Changqing Liu; Hongwei Fan; Tao Xi; Jing Xiong
Journal:  Br J Pharmacol       Date:  2017-03-03       Impact factor: 8.739

3.  1H NMR-based metabolic profiling reveals the effects of fluoxetine on lipid and amino acid metabolism in astrocytes.

Authors:  Shunjie Bai; Chanjuan Zhou; Pengfei Cheng; Yuying Fu; Liang Fang; Wen Huang; Jia Yu; Weihua Shao; Xinfa Wang; Meiling Liu; Jingjing Zhou; Peng Xie
Journal:  Int J Mol Sci       Date:  2015-04-15       Impact factor: 5.923

4.  Interleukin-6 Induces DEC1, Promotes DEC1 Interaction with RXRα and Suppresses the Expression of PXR, CAR and Their Target Genes.

Authors:  Rui Ning; Yunran Zhan; Shuangcheng He; Jinhua Hu; Zhu Zhu; Gang Hu; Bingfang Yan; Jian Yang; Wei Liu
Journal:  Front Pharmacol       Date:  2017-11-28       Impact factor: 5.810

5.  Regulation of hippocampal neuronal apoptosis and autophagy in mice with sepsis-associated encephalopathy by immunity-related GTPase M1.

Authors:  Rui-Xi Zhou; Yu-Yao Li; Yi Qu; Qun Huang; Xue-Mei Sun; De-Zhi Mu; Xi-Hong Li
Journal:  CNS Neurosci Ther       Date:  2019-10-14       Impact factor: 5.243

Review 6.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

Review 7.  Novel Findings regarding the Bioactivity of the Natural Blue Pigment Genipin in Human Diseases.

Authors:  Magdalena Bryś; Karina Urbańska; Beata Olas
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.